Please amend the paragraph on page 10, lines 5-7, as follows:

Still another preferred embodiment of this invention contemplates that the ligand-receptor binding pair is selected from the group consisting of: biotin-streptavidin; ~~streptavidin;;~~ and antigen-antibody.

Please amend the paragraph on page 12, lines 9-22, as follows:

"Photosensitizing agent" is a chemical compound which homes to one or more types of selected target cells and, when contacted by radiation, absorbs the light, which results in impairment or destruction of the target cells. Virtually any chemical compound that homes to a selected target and absorbs light may be used in this invention. Preferably, the chemical compound is nontoxic to the animal to which it is administered or capable of being formulated in a nontoxic composition. Preferably, the chemical compound in its photodegraded form is also nontoxic. A comprehensive listing of photosensitive chemicals may be found in Kreimer-Birnbaum, Sem. Hematol. 26:157-73, 1989. Photosensitive compounds include, but are not limited to, chlorins, bacteriochlorins, phthalocynanines, porphyrins, purpurins, merocyanines, psoralens, benzoporphyrin derivatives (BPD) and porfimer sodium and pro-drugs such as ~~.delta.-aminolevulinic~~ δ-aminolevulinic acid, which can produce drugs such as protoporphyrin. Other compounds include indocyanine green (ICG); methylene blue; toluidine blue; texaphyrins; and any other agent that absorbs light in a range of 500 nm - 1100 nm.

Please amend the paragraph on page ~~8~~ 15, line ~~32~~ 24 through page ~~9~~ 16, line ~~11~~ 17, as follows:

ycc 4/19/10

Additionally, the present invention is drawn to a method for transcutaneous ultrasonic therapy of tumors in a mammalian subject or patient by first administering to the subject a therapeutically effective amount of a first conjugate comprising a first member of a ligand-receptor binding pair conjugated to an antibody or antibody fragment, wherein said antibody or antibody fragment selectively binds to a target antigen of thick or thin neointimas, arterial plaques, ~~plaques,;~~ vascular smooth muscle cells and/or the abnormal